ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

HER2-Positive Breast Cancer

HER2-Positive Breast Cancer

The presence of the truncated form of human epidermal growth factor receptor 2 (p95HER2) in circulating tumor cells is associated with poor survival in breast cancer patients.

Both chemotherapy and anti-HER2 therapy can improve survival in HER2-positive breast cancer patients with brain metastases who undergo whole-brain radiotherapy.

Breast cancer patients with PIK3CA gene mutations may not benefit from dual anti-HER2 inhibition, according to a new study in The Oncologist.

Using a novel imaging technique, researchers have discovered that differences in HER2 homodimers on breast cancer cells may point toward functional differences, with possible implications for metastasis and drug resistance.

[18F]FDG-PET/CT could predict response in patients with metastatic HER2-positive breast cancer treated with lapatinib plus trastuzumab.

Neoadjuvant TDM-1 was shown to be effective in treating HER2-positive, HR-positive breast cancer compared with trastuzumab, with or without endocrine therapy.

The addition of pertuzumab to trastuzumab and docetaxel offers significant improvement over other options in patients with HER2-positive breast cancer.

Pages

Subscribe to HER2-Positive Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.